Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leads and Contacts 0208

This article was originally published in RPM Report

Executive Summary

FDA Office of New Drugs Director John Jenkins has 17 drug divisions that report to him. These are the divisions and current directors.

You may also be interested in...



FDA's Outlook on the Drug Approval Drought

You would have to go back a quarter century to find a year with as few new drug approvals as 2007. There may be no one more concerned with the sinking approval rate of new molecular entities than FDA's Office of New Drugs Director John Jenkins. The RPM Report asked Jenkins why the stream of NMEs coming on to the market has slowed to a trickle.

FDA Insider: Agency Looks Carefully Inside for New CDER Head

FDA’s Center for Drug Evaluation & Research still doesn’t have a permanent director. The longer the search goes on, the more likely the candidate will come from inside.

FDA Insider: Agency Looks Carefully Inside for New CDER Head

FDA’s Center for Drug Evaluation & Research still doesn’t have a permanent director. The longer the search goes on, the more likely the candidate will come from inside.

Related Content

Topics

UsernamePublicRestriction

Register

PS080397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel